What are the treatment recommendations for a 42-year-old woman with no prior medical history who has low high‑density lipoprotein (HDL), borderline high low‑density lipoprotein (LDL), and vitamin D insufficiency, with all other laboratory values normal?

Treatment Recommendations

This 42-year-old woman with low HDL (35 mg/dL), borderline-high LDL (110 mg/dL), and vitamin D insufficiency (28 ng/mL) should begin intensive lifestyle modifications targeting her lipid abnormalities, with vitamin D supplementation of 1000-2000 IU daily, and does not require statin therapy at this time given her low absolute cardiovascular risk.

Risk Stratification

This patient requires cardiovascular risk assessment before determining treatment intensity. As a 42-year-old woman with no prior medical history, normal blood pressure (implied by normal labs), and no diabetes, she likely falls into a low-to-intermediate risk category (10-year ASCVD risk <10-20%) 1.

Key lipid abnormalities identified:

• HDL-C of 35 mg/dL (goal >50 mg/dL in women) 1
• LDL-C of 110 mg/dL (optimal <100 mg/dL) 1
• Vitamin D of 28 ng/mL (insufficient; optimal ≥30 ng/mL)

Lipid Management Strategy

Lifestyle Modifications (Class I, Level B)

Initiate comprehensive lifestyle therapy as first-line treatment 1:

• Dietary modifications:

  • Limit saturated fat to <10% of calories (or <7% if pursuing aggressive lipid lowering) 1
  • Limit cholesterol intake to <300 mg/day 1
  • Minimize trans-fatty acids to <1% of energy 1
  • Increase consumption of fruits, vegetables, whole grains, low-fat dairy, fish, and legumes 1

• Physical activity:

  • Minimum 150 minutes/week of moderate-intensity aerobic activity 1

• Weight management:

  • Maintain BMI between 18.5-24.9 kg/m² and waist circumference <35 inches 1

• Smoking cessation (if applicable) 1

Pharmacotherapy Considerations

Statin therapy is NOT indicated at this time based on current guidelines 1. The 2007 AHA guidelines specify that LDL-lowering therapy in lower-risk women should be considered only when:

• LDL-C ≥190 mg/dL (regardless of risk factors), OR
• LDL-C ≥160 mg/dL with multiple risk factors, OR
• LDL-C ≥130 mg/dL with multiple risk factors AND 10-year risk 10-20% 1

Her LDL of 110 mg/dL does not meet these thresholds.

For isolated low HDL-C: Niacin or fibrate therapy may be considered (Class IIb, Level B) in women with multiple risk factors and 10-year absolute risk 10-20% after LDL-C goal is reached 1. However, given her likely low absolute risk and the lack of established cardiovascular disease, pharmacologic therapy for HDL is not warranted at this time. Recent evidence shows that specific HDL-raising therapies have been disappointing in clinical outcomes 2.

Important Caveat

The guidelines emphasize that in women, HDL-C and triglyceride levels are better predictors of coronary risk than LDL-C 3. While her low HDL is concerning, lifestyle modifications remain the most appropriate initial intervention for a low-risk patient.

Vitamin D Management

Recommend vitamin D supplementation of 1000-2000 IU daily to achieve levels ≥30 ng/mL. Her current level of 28 ng/mL represents insufficiency.

Important considerations regarding vitamin D and lipids:

• Recent evidence shows conflicting effects of vitamin D supplementation on lipid profiles 4, 5, 6
• One 2018 RCT found vitamin D supplementation actually increased triglycerides, total cholesterol, and ApoB 5
• However, a 2026 meta-analysis in metabolic syndrome patients showed vitamin D reduced triglycerides and potentially increased HDL-C with daily regimens 6
• The lipid-modifying effects appear most beneficial in patients with baseline vitamin D <30 ng/mL and pre-existing hyperlipidemia 4

Given the mixed evidence, vitamin D supplementation should be pursued primarily for bone health and general wellness, not as a lipid-lowering strategy. The association between vitamin D deficiency and dyslipidemia is stronger in women 7, but causality remains uncertain.

Follow-Up Plan

Reassess in 3-6 months with repeat lipid panel and vitamin D level after implementing lifestyle modifications and vitamin D supplementation. At that time:

• If LDL-C remains >130 mg/dL despite lifestyle therapy, calculate 10-year ASCVD risk using pooled cohort equations 8
• Consider risk-enhancing factors specific to women (if applicable): premature menopause, pregnancy-associated conditions, polycystic ovarian syndrome 9
• If HDL-C remains <40 mg/dL and cardiovascular risk is elevated, reassess need for pharmacotherapy

Aspirin Consideration

Aspirin is NOT recommended for this patient. In women <65 years of age, aspirin should only be considered when the benefit for ischemic stroke prevention clearly outweighs bleeding risk (Class IIb, Level B) 1. For low-risk patients, potential benefits do not outweigh risks of gastrointestinal bleeding 10.